Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development and commercialization of a pharmaceutical product and the development of a product candidate for the treatment of obesity. Its combination product candidates for obesity are ND32 (formerly Contrave), which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. The Company has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The Company retains marketing rights for NB32 outside the United States, Canada and Mexico and worldwide marketing rights for Empatic. The Company is developing its product candidates for large markets traditionally served by primary care physicians.